Here are the results for the second quarter of 2025 from Johnson & Johnson $JNJ (+0,57 %)
🧾 Sales & earnings (Q2 2025)
- SalesUSD 23.74 billion (increase of 5.8% compared to Q2 2024)
- Net result (GAAP)USD 5.54 billion (increase of 18.2%)
- EPS (GAAP, diluted)USD 2.29 (increase of 18.7%)
- EPS (non-GAAP)USD 2.77 (decrease of 1.8 %)
- Effective tax rate (GAAP): 14,7 %
- Gross margin: 67,9 %
🔬 Segment development
Innovative Medicine
- Sales: USD 15.2 billion (+4.9 %)
- Growth particularly in oncology products such as DARZALEX (+23 % YoY worldwide)
- Declines in immunology (e.g. STELARA: -43 %)
MedTech
- Sales: USD 8.54 billion (+7.3 %)
- Strong growth in the areas of Cardiovascular (+23.5 %) and Electrophysiology (+11,0 %)
- Weak development in Orthopaedics (-0,3 %)
🌎 Regional development (Q2 2025)
- USA13.54 billion USD sales (+7.8 %)
- International10.20 billion USD sales (+3.2 %)
- WorldwideUSD 23.74 billion (+5.8 %)
🧮 Half-year results (H1 2025)
- TurnoverUSD 45.64 billion (+4.1 %)
- Net result (GAAP)USD 16.54 billion (+108.2%)
- EPS (GAAP)6.82 USD (+108.6 %)
- EPS (Non-GAAP)5.53 USD (±0 %)
⚖️ Key balance sheet figures
- CET1/capital-related figures are not shown in the report, but the operating profit before taxes (GAAP) shows an increase of 12,9 % YoY.
- Effective tax rate decreased from 18.5% to 14.7% (Q2 YoY comparison).
📌 Conclusion
Johnson & Johnson delivers strong results in the second quarter of 2025 with double-digit profit growth. Sales increases in Oncology and MedTech had a particularly positive impact. A decline in sales in the Immunology segment had a dampening effect. The company reaffirms its robust position with stable margins and strong cash flows in the first half of the year.
